Timeliness of reperfusion in ST-segment elevation myocardial infarction and outcomes in Kerala, India: results of the TRUST outcomes registry.

IF 3.6 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Postgraduate Medical Journal Pub Date : 2024-10-04 DOI:10.1093/postmj/qgae129
Anoop Mathew, Muhammad Moolla, Panniyammakal Jeemon, Eapen Punnoose, S M Ashraf, Sunil Pisharody, Sunitha Viswanathan, T G Jayakumar, Abdullakutty Jabir, Jubil P Mathew, Thomas John, Vinod Thomas, Kevin Bainey
{"title":"Timeliness of reperfusion in ST-segment elevation myocardial infarction and outcomes in Kerala, India: results of the TRUST outcomes registry.","authors":"Anoop Mathew, Muhammad Moolla, Panniyammakal Jeemon, Eapen Punnoose, S M Ashraf, Sunil Pisharody, Sunitha Viswanathan, T G Jayakumar, Abdullakutty Jabir, Jubil P Mathew, Thomas John, Vinod Thomas, Kevin Bainey","doi":"10.1093/postmj/qgae129","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Transatlantic guidelines endorse quality metrics for timely reperfusion in patients with ST-elevation myocardial infarction (STEMI). Compliance in low- and middle-income countries (LMICs) is largely unknown.</p><p><strong>Study design: </strong>We prospectively evaluated 2928 STEMI patients in Kerala, India, across 16 PCI-capable hospitals who received reperfusion with either primary percutaneous coronary intervention (PPCI) or fibrinolysis. Primary endpoint was a major adverse cardiovascular event (MACE) composite of death, non-fatal myocardial infarction, stroke or readmission for heart failure at 1-year.</p><p><strong>Results: </strong>Among reperfused STEMI patients, 320 (10.9%) received timely reperfusion with either PPCI or fibrinolysis, 1985 (67.8%) received delayed PPCI, and 623 (21.3%) received delayed fibrinolysis. Timely reperfusion had lower unadjusted MACE rates than delayed PCI or fibrinolysis (timely reperfusion: 11.9%, delayed PPCI: 13.6%, delayed fibrinolysis: 23.9%, P < 0.001). Mortality was lowest in the timely reperfusion group (timely reperfusion: 6.3%, delayed PPCI: 7.8%, delayed fibrinolysis 18.8%, P < 0.001). After multivariate analysis, delayed fibrinolysis had a higher MACE rate (HR 1.52 95% CI 1.04-2.21) and mortality (HR 1.97, 95% CI 1.18-3.25) compared to timely reperfusion. Total ischemic time > 3 h and delayed first medical contact-to-needle time predicted MACE at 1 year.</p><p><strong>Conclusions: </strong>Among STEMI patients in Kerala, India, only one in 10 eligible patients received timely reperfusion. Longer total ischemic times and delayed fibrinolysis were associated with 1-year MACE. Improving timely reperfusion is critical to enhancing STEMI outcomes in LMICs. What is already known on this topic Given the established link between delay to reperfusion and worse major adverse cardiac events (MACE), global efforts have concentrated on minimizing different components of the total ischemic time to improve ST-elevation myocardial infarction (STEMI) outcomes. Compliance in low- and middle-income countries (LMICs) is largely unknown. What this study adds In this cohort of STEMI patients in Kerala, India, total ischemic time and first medical contact-to-needle time correlated with long-term MACE rates, whereas other timeliness indicators did not. How this study might affect research, practice or policy Our study highlights the significant barriers to accessing STEMI care that are prevalent in LMICs despite incremental growth in the number of PCI-capable hospitals. The pre-hospital phase within total ischemic time is the most important quality improvement metric of STEMI care in LMICs, especially for patients chosen for fibrinolysis.</p>","PeriodicalId":20374,"journal":{"name":"Postgraduate Medical Journal","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postgraduate Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/postmj/qgae129","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Transatlantic guidelines endorse quality metrics for timely reperfusion in patients with ST-elevation myocardial infarction (STEMI). Compliance in low- and middle-income countries (LMICs) is largely unknown.

Study design: We prospectively evaluated 2928 STEMI patients in Kerala, India, across 16 PCI-capable hospitals who received reperfusion with either primary percutaneous coronary intervention (PPCI) or fibrinolysis. Primary endpoint was a major adverse cardiovascular event (MACE) composite of death, non-fatal myocardial infarction, stroke or readmission for heart failure at 1-year.

Results: Among reperfused STEMI patients, 320 (10.9%) received timely reperfusion with either PPCI or fibrinolysis, 1985 (67.8%) received delayed PPCI, and 623 (21.3%) received delayed fibrinolysis. Timely reperfusion had lower unadjusted MACE rates than delayed PCI or fibrinolysis (timely reperfusion: 11.9%, delayed PPCI: 13.6%, delayed fibrinolysis: 23.9%, P < 0.001). Mortality was lowest in the timely reperfusion group (timely reperfusion: 6.3%, delayed PPCI: 7.8%, delayed fibrinolysis 18.8%, P < 0.001). After multivariate analysis, delayed fibrinolysis had a higher MACE rate (HR 1.52 95% CI 1.04-2.21) and mortality (HR 1.97, 95% CI 1.18-3.25) compared to timely reperfusion. Total ischemic time > 3 h and delayed first medical contact-to-needle time predicted MACE at 1 year.

Conclusions: Among STEMI patients in Kerala, India, only one in 10 eligible patients received timely reperfusion. Longer total ischemic times and delayed fibrinolysis were associated with 1-year MACE. Improving timely reperfusion is critical to enhancing STEMI outcomes in LMICs. What is already known on this topic Given the established link between delay to reperfusion and worse major adverse cardiac events (MACE), global efforts have concentrated on minimizing different components of the total ischemic time to improve ST-elevation myocardial infarction (STEMI) outcomes. Compliance in low- and middle-income countries (LMICs) is largely unknown. What this study adds In this cohort of STEMI patients in Kerala, India, total ischemic time and first medical contact-to-needle time correlated with long-term MACE rates, whereas other timeliness indicators did not. How this study might affect research, practice or policy Our study highlights the significant barriers to accessing STEMI care that are prevalent in LMICs despite incremental growth in the number of PCI-capable hospitals. The pre-hospital phase within total ischemic time is the most important quality improvement metric of STEMI care in LMICs, especially for patients chosen for fibrinolysis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
印度喀拉拉邦 ST 段抬高型心肌梗死患者再灌注的及时性与预后:TRUST 预后登记的结果。
目的:跨大西洋指南认可了 ST 段抬高型心肌梗死(STEMI)患者及时再灌注的质量标准。研究设计:我们对印度喀拉拉邦 16 家具备 PCI 能力的医院的 2928 名 STEMI 患者进行了前瞻性评估,这些患者接受了初级经皮冠状动脉介入治疗 (PPCI) 或纤维蛋白溶解术进行再灌注。主要终点是死亡、非致死性心肌梗死、中风或1年后因心力衰竭再次入院的主要不良心血管事件(MACE)综合结果:在再灌注的 STEMI 患者中,320 人(10.9%)接受了及时的再灌注,包括 PPCI 或纤维蛋白溶解,1985 人(67.8%)接受了延迟的 PPCI,623 人(21.3%)接受了延迟的纤维蛋白溶解。及时再灌注的未调整MACE发生率低于延迟PCI或纤维蛋白溶解(及时再灌注:11.9%,延迟PPCI:13.6%,延迟纤维蛋白溶解:23.9%,P<0.001)。及时再灌注组的死亡率最低(及时再灌注:6.3%,延迟 PPCI:7.8%,延迟纤维蛋白溶解:18.8%,P<0.001)。经过多变量分析,与及时再灌注相比,延迟纤溶的MACE率(HR 1.52 95% CI 1.04-2.21)和死亡率(HR 1.97,95% CI 1.18-3.25)更高。总缺血时间大于3小时和首次医疗接触到插针时间延迟预测了1年后的MACE:在印度喀拉拉邦的STEMI患者中,每10名符合条件的患者中只有1人得到及时再灌注。总缺血时间较长和纤维蛋白溶解延迟与 1 年后的 MACE 有关。改善及时再灌注对提高低收入国家 STEMI 的预后至关重要。有关该主题的已知信息 鉴于再灌注延迟与主要不良心脏事件(MACE)恶化之间的既定联系,全球努力的重点是尽量缩短总缺血时间的不同组成部分,以改善 STEMI(ST 段抬高型心肌梗死)的预后。中低收入国家(LMICs)的遵医情况在很大程度上还不为人所知。本研究的补充 在印度喀拉拉邦的这组 STEMI 患者中,总缺血时间和首次医疗接触到插针时间与长期 MACE 发生率相关,而其他及时性指标则不相关。本研究可能对研究、实践或政策产生的影响 我们的研究突出表明,尽管具备PCI能力的医院数量在不断增加,但在低收入、中等收入国家和地区,STEMI治疗仍普遍存在重大障碍。总缺血时间内的院前阶段是低收入国家 STEMI 治疗最重要的质量改进指标,尤其是对选择纤溶的患者而言。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Postgraduate Medical Journal
Postgraduate Medical Journal 医学-医学:内科
CiteScore
8.50
自引率
2.00%
发文量
131
审稿时长
2.5 months
期刊介绍: Postgraduate Medical Journal is a peer reviewed journal published on behalf of the Fellowship of Postgraduate Medicine. The journal aims to support junior doctors and their teachers and contribute to the continuing professional development of all doctors by publishing papers on a wide range of topics relevant to the practicing clinician and teacher. Papers published in PMJ include those that focus on core competencies; that describe current practice and new developments in all branches of medicine; that describe relevance and impact of translational research on clinical practice; that provide background relevant to examinations; and papers on medical education and medical education research. PMJ supports CPD by providing the opportunity for doctors to publish many types of articles including original clinical research; reviews; quality improvement reports; editorials, and correspondence on clinical matters.
期刊最新文献
A Mendelian analysis of the causality between inflammatory cytokines and digestive tract cancers. Cholecystectomy and cancer risk: evidence from National Health and Nutrition Examination Survey and Mendelian randomization. The key to addressing the issue of academic misconduct in the medical field is to reform the evaluation system. Timeliness of reperfusion in ST-segment elevation myocardial infarction and outcomes in Kerala, India: results of the TRUST outcomes registry. Variation of brain natriuretic peptide assists with volume management and predicts prognosis of hemodialysis patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1